Paclitaxel (Taxol) attenuates clinical disease in a spontaneously demyelinating transgenic mouse and induces remyelination

  title={Paclitaxel (Taxol) attenuates clinical disease in a spontaneously demyelinating transgenic mouse and induces remyelination},
  author={M. Moscarello and B. Mak and T. A. Nguyễn and D. Wood and F. Mastronardi and S. Ludwin},
  journal={Multiple Sclerosis},
  pages={130 - 138}
  • M. Moscarello, B. Mak, +3 authors S. Ludwin
  • Published 2002
  • Medicine
  • Multiple Sclerosis
  • Treatment with paclitaxel by four intraperitoneal injections (20 mg/kg) 1 week apart attenuated clinical signs in a spontaneously demyelinating model, if given with onset of clinical signs. If given at 2 months of age (1 month prior to clinical signs), disease was almost completely prevented. The astrogliosis, prominent in our model, was reversed by paclitaxel as determined by astrocyte counts and quantitation of GFAP. Electron microscopic examination of affected regions at 2.5 months… CONTINUE READING
    42 Citations
    Synergy between paclitaxel plus an exogenous methyl donor in the suppression of murine demyelinating diseases
    • 22
    Remyelination in multiple sclerosis
    • 67
    Attenuation of Experimental Autoimmune Encephalomyelitis and Nonimmune Demyelination by IFN-β plus Vitamin B12: Treatment to Modify Notch-1/Sonic Hedgehog Balance 1
    • 71
    • PDF
    Differential expression of sonic hedgehog immunoreactivity during lesion evolution in autoimmune encephalomyelitis.
    • 37
    • Highly Influenced
    • PDF
    Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study.
    • 53
    Multiple Sclerosis
    • 149
    • PDF
    Peptidylarginine deiminase 2 (PAD2) overexpression in transgenic mice leads to myelin loss in the central nervous system
    • 107
    • PDF
    Myelin Basic Protein Citrullination in Multiple Sclerosis: A Potential Therapeutic Target for the Pathology
    • 41
    Natalizumab: A new treatment for relapsing remitting multiple sclerosis
    • M. Hutchinson
    • Medicine
    • Therapeutics and clinical risk management
    • 2007
    • 79
    • PDF


    Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis.
    • G. Wolswijk
    • Biology, Medicine
    • Brain : a journal of neurology
    • 2000
    • 195
    • PDF